A
Benign
Bladder cancer
HACAT
hbSMC
HTR8
N155
RT112
T24
Viability (%)
Control
HT
Elesclomol (nM)
B
IC50 of elesclomol
Control
HT
T24
RT112
HTR8
hbSMC
HACAT
N155
C
IC50-based TER of elesclomol
T24
RT112
HTR8
hbSMC
HACAT
N155